You haven't searched anything yet.
Who is BlueRock?
BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique cell gene platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases.
The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel cell gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.
What Are We Doing?
Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.
We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.
We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting-edge cellular therapies to impact patients’ lives.
Director of Toxicology leads nonclinical safety within Preclinical Development and is responsible for coordinating nonclinical safety to adequately support BlueRock programs from research through development stages. Working across numerous functional groups and testing facilities, the position is accountable for all phases of nonclinical safety of human induced pluripotent stem cell (hiPSC)-derived authentic cells prior to initiating clinical trials. Director of Toxicology assures adequate strategy for nonclinical IND-enabling studies in conjunction with program teams to support clinical testing and provides input as a technical expert within the immediate function and within a multidisciplinary project team.
This dynamic position works closely with program team members across various functional groups within BlueRock, assures nonclinical development studies (both GLP and non-GLP) are performed according to the study protocol at external CROs, and compiles nonclinical documents for regulatory submissions. An ideal employee will be passionate to contribute to advance programs and to deliver safe cell therapies to patients.
\nResponsibilities:
#LI-AL1
BlueRock Therapeutics Company Culture Highlights
Winner of Boston Business Journal's Best Places to Work (Mid-size Company) 2023
Winner of Comparably's Award for Best Company for Diversity 2022
Winner of Comparably's Award for Best Company for Women 2022
Winner of Comparably's Award for Best CEO 2022
BlueRock Therapeutics is ranked in the top 5% of companies for Overall Culture on Comparably.
Engineering Department is ranked in the top 5% of companies for Overall Culture on Comparably.
Check us out on Comparably: https://www.comparably.com/companies/bluerock-therapeutics
Follow us on Linkedin: https://www.linkedin.com/company/bluerocktx/
Equal Opportunity Workplace:At BlueRock, we welcome and support differences and diversity and we are proud to be an equal opportunity workplace. Please let us know if you require disability-related accommodation or other grounds protected by human rights legislation during the recruitment process so that we can work with you to meet your needs.
Full Time
Social & Legal Services
$126k-162k (estimate)
04/18/2024
05/16/2024
alexandrianyc.com
MANHATTAN, NY
<25
2016
ELISABETH SYDOR
<$5M
Social & Legal Services